A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig Hofmeister
Dr. Craig Hofmeister, multiple myeloma specialist from Emory, presents an update on the role of CAR-T therapy in multiple myeloma. What products are currently FDA approved and what new products have been developed? Will the product become more widely available? Will it ever become front-line therapy? The answers to these questions and more will be discussed in this important meeting.
Audrey introduces the agenda of the event and featured speaker Stephanie Wiese.
Dr. Craig Hofmeister presents an update on the role of CAR-T therapy in multiple myeloma.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Craig Hofmeister
Craig C. Hofmeister, MD, MPH, is Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in internal medicine and hematology, Dr. Hofmeister’s practice focuses on plasma cell cancers, including plasmacytomas, multiple myeloma, AL amyloidosis, smoldering myeloma, and monoclonal gammopathies of renal significance. He started practicing with Emory Healthcare in 2018.